This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.
Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:1043. vi
Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biologic features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10.
Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel S. Patients’ age and BCR-ABL frequency in adult B-cell precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–9.
Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.
Chereda B, Melo JV. The biology and pathogenesis of chronic myeloid leukemia. In: Hehlmann R, editor. Chronic myeloid leukemia. Switzerland: Springer International Publishing; 2016. p. 17–40.
Ravandi F, O’Brien S, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–64.
Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. an international overview. Leukemia. 2019. https://doi.org/10.1038/s41375-018-0341-4.
Hai A, Kizilbash NA, Zaidi SH, Alruwaili J, Shahzad K. Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation. 2014;10:108–14.
Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimomdo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–8.
Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–8.
Malagola M, Papayannidis C, Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol. 2016;95:681–93.
Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simoes MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742–50.
Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differences in structural elements of bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Leukemia. 2017;31:1502–15.
Cutler J, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS. Differential signaling through p190 and p210 BCR-ABL fusion proteins reveales by interactome and phosphoproteome analysis. Leukemia. 2017;31:1513–24.
Acknowledgements
This work was supported in part by the European Leukemia Net Foundation and by AIRC 5×1000 (21198). The technical assistance of Mrs Chiara Ferri is kindly acknowledged.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Baccarani, M., Iacobucci, I., Chiaretti, S. et al. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia 34, 929–931 (2020). https://doi.org/10.1038/s41375-019-0591-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0591-9
This article is cited by
-
Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report
Journal of Medical Case Reports (2021)
-
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
Leukemia (2021)